Resistance to EGFR-Targeted Therapy: A Family Affair

Keyphrases

• ErbB2 100%
• Family Affairs 100%
• EGFR-targeted Therapy 100%
• Monotherapy 50%
• Colorectal Cancer 50%
• Head-and-neck Cancer 50%
• Clinical Benefit 50%
• Cetuximab 50%
• ErbB4 50%
• Heregulin 50%
• ErbB3 50%
• Cetuximab Resistance 50%

Medicine and Dentistry

• Targeted Therapy 100%
• Epidermal Growth Factor Receptor 100%
• Cetuximab 100%
• Monotherapy 50%
• Head and Neck Cancer 50%
• Colorectal Carcinoma 50%
• Neu Differentiation Factor 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Epidermal Growth Factor Receptor 100%
• Cetuximab 100%
• Monotherapy 50%
• Head and Neck Cancer 50%
• Colorectal Carcinoma 50%
• Neu Differentiation Factor 50%